Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease

Cell Cycle

Volumn 13, Issue 9, 2014, Pages 1489-1494

  Aravinthan, Aloysious ^a   Mells, George ^a   Allison, Michael ^a   Leathart, Julian ^b   Kotronen, Anna ^c   Yki Jarvinen, Hannele ^c   Daly, Ann K ^b   Day, Christopher P ^b   Anstee, Quentin M ^b   Alexander, Graeme ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cell cycle inhibitor p21; Chronic liver disease; Liver fibrosis; Polymorphism; Senescence

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN P21; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; FINLAND; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; SENESCENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT; CELL AGING; CLINICAL TRIAL; ENGLAND; GENETIC ASSOCIATION STUDY; GENETICS; LIVER CIRRHOSIS; METABOLISM; MULTICENTER STUDY; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CELL AGING; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; ENGLAND; FEMALE; FINLAND; GENETIC ASSOCIATION STUDIES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84899750753     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28471     Document Type: Article

References (39)

1. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130:223-33; PMID:17662938; http://dx.doi.org/10.1016/j.cell.2007.07. 003
2. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729-40; PMID:17667954; http://dx.doi.org/10.1038/nrm2233
3. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005; 37:961-76; PMID:15743671; http://dx.doi.org/10.1016/j.biocel.2004.10.013
4. Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007; 133:80-90; PMID:17631134; http://dx.doi.org/10.1053/j.gastro.2007.05.012
5. Nakajima T, Moriguchi M, Katagishi T, Sekoguchi S, Nishikawa T, Takashima H, Kimura H, Minami M, Itoh Y, Kagawa K, et al. Premature telomere shortening and impaired regenerative response in hepatocytes of individuals with NAFLD. Liver Int 2006; 26:23-31; PMID:16420506; http://dx.doi.org/10.1111/j.1478-3231. 2005.01178.x
6. Nakajima T, Nakashima T, Okada Y, Jo M, Nishikawa T, Mitsumoto Y, Katagishi T, Kimura H, Itoh Y, Kagawa K, et al. Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non-alcoholic fatty liver disease: Comparison with telomere-specific quantitative FISH and p21 immunohistochemistry. Pathol Int 2010; 60:175-83; PMID:20403043; http://dx.doi.org/10.1111/j.1440-1827.2009.02504.x
7. Sasaki M, Ikeda H, Yamaguchi J, Miyakoshi M, Sato Y, Nakanuma Y. Bile ductular cells undergoing cellular senescence increase in chronic liver diseases along with fibrous progression. Am J Clin Pathol 2010; 133:212-23; PMID:20093230; http://dx.doi.org/10.1309/AJCPWMX47TREYWZG
8. Sasaki M, Ikeda H, Yamaguchi J, Nakada S, Nakanuma Y. Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing cellular senescence. Hepatology 2008; 48:186-95; PMID:18536059; http://dx.doi.org/10.1002/hep.22348
9. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, Zender L, Lowe SW. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134:657-67; PMID:18724938; http://dx.doi.org/10.1016/j.cell.2008.06. 049
10. Marshall A, Rushbrook S, Davies SE, Morris LS, Scott IS, Vowler SL, Coleman N, Alexander G. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology 2005; 128:33-42; PMID:15633121; http://dx.doi.org/10.1053/j. gastro.2004.09.076
11. Aravinthan A, Scarpini C, Tachtatzis P, Verma S, Penrhyn-Lowe S, Harvey R, Davies SE, Allison M, Coleman N, Alexander G. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J Hepatol 2013; 58:549-56; PMID:23142622; http://dx.doi.org/10.1016/j.jhep.2012.10.031
12. Aravinthan A, Pietrosi G, Hoare M, Jupp J, Marshall A, Verrill C, Davies S, Bateman A, Sheron N, Allison M, et al. Hepatocyte expression of the senescence marker p21 is linked to fibrosis and an adverse liver-related outcome in alcohol-related liver disease. PLoS One 2013; 8:e72904; PMID:24086266; http://dx.doi.org/10.1371/journal.pone.0072904
13. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, Gao B. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012; 56:1150-9; PMID:22473749; http://dx.doi.org/10.1002/hep.25744
14. Klein S, Klösel J, Schierwagen R, Körner C, Granzow M, Huss S, Mazar IG, Weber S, van den Ven PF, Pieper-Fürst U, et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 2012; 92:1440-50; PMID:22890553; http://dx.doi.org/10.1038/labinvest.2012.106
15. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28:339-50; PMID:18956290; http://dx.doi.org/10.1055/s-0028-1091978
16. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202-19; PMID:12717402; http://dx.doi.org/10.1053/jhep.2003.50193
17. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48(Suppl 1):S104-12; PMID:18304679; http://dx.doi.org/10.1016/j.jhep.2008.01.009
18. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10:330-44; PMID:23507799; http://dx.doi.org/10.1038/nrgastro.2013.41
19. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356-62; PMID:10573511; http://dx.doi.org/10.1002/hep.510300604
20. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121:91-100; PMID:11438497; http://dx.doi.org/10. 1053/gast.2001.25540
21. Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis 2011; 31:128-46; PMID:21538280; http://dx.doi.org/10.1055/s-0031-1276643
22. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006; 87:1-16; PMID:16436109; http://dx.doi.org/10.1111/j.0959-9673.2006.00465.x
23. Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, Leathart JB, Pietrobattista A, Burt AD, Maggioni M, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010; 59:267-73; PMID:20176643; http://dx.doi.org/10.1136/gut.2009.190801
24. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45:1366-74; PMID:17476695; http://dx.doi.org/10.1002/hep.21655
25. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, Nash CRN; NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52:894-903; PMID:20684021; http://dx.doi.org/10.1002/hep.23759
26. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology 2010; 139:1567-76, e1-6; PMID:20708005; http://dx.doi.org/10.1053/j.gastro.2010. 07.057
27. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51:1209-17; PMID:20373368; http://dx.doi.org/10.1002/hep.23622
28. Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 2012; 56:448-54; PMID:21756849; http://dx.doi.org/10.1016/j.jhep.2011.05.029
29. Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T, Mawatari H, Iida H, Kato S, Fujita K, Takahashi H, et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 2009; 29:1078-85; PMID:19302184; http://dx.doi.org/10.1111/j.1478- 3231.2009.01988.x
30. Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, Abate M, Friedman SL, Narla G, Bugianesi E, et al. The Kruppel-like factor 6 geno-type is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008; 135:282-91, e1; PMID:18515091; http://dx.doi.org/10.1053/j.gastro.2008.04. 004
31. Dixon JB, Bhathal PS, Jonsson JR, Dixon AF, Powell EE, O'Brien PE. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003; 39:967-71; PMID:14642613; http://dx.doi.org/10.1016/ S0168-8278(03)00459-8
32. Korthagen NM, van Moorsel CH, Barlo NP, Kazemier KM, Ruven HJ, Grutters JC. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. PLoS One 2012; 7:e30442; PMID:22291954; http://dx.doi.org/10.1371/ journal.pone.0030442
33. Ma H, Chen J, Pan S, Dai J, Jin G, Hu Z, Shen H, Shu Y. Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population. Lung Cancer 2011; 73:32-7; PMID:21145615; http://dx.doi.org/10.1016/j.lungcan.2010.11.001
34. Kong EK, Chong WP, Wong WH, Lau CS, Chan TM, Ng PK, Song YQ, Mak W, Lau YL. p21 gene polymorphisms in systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46:220-6; PMID:16837471; http://dx.doi.org/10.1093/rheumatology/ kel210
35. Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010; 29:273-83; PMID:20390322; http://dx.doi.org/10.1007/s10555-010-9220-9
36. Tomita K, Teratani T, Suzuki T, Oshikawa T, Yokoyama H, Shimamura K, Nishiyama K, Mataki N, Irie R, Minamino T, et al. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice. J Hepatol 2012; 57:837-43; PMID:22641095; http://dx.doi.org/10.1016/j. jhep.2012.05.013
37. Campisi J. The role of cellular senescence in skin aging. The journal of investigative dermatology Symposium proceedings / the Society for Investigative Dermatology, Inc [and] European Society for Dermatological Research 1998; 3:1-5.
38. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-74; PMID:10484010; http://dx.doi.org/10.1111/j.1572-0241.1999.01377.x
39. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996; 6:319-28; PMID:8873218; http://dx.doi.org/10.1097/00008571-199608000-00005